GlassScriptPhysician profile
Sammy Lerma
NPI 1871571950
$2,469.11
in general payments reported to CMS, 2019-2025
29 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $268 · 2021: $313 · 2022: $95.49 · 2023: $639 · 2024: $247 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $322.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $262.94 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $248.61 | 2019-2025 | |
| Nalu Medical, INC. | $241.83 | 2023 | Nalu Neurostimulation System |
| Abbott Laboratories | $182.28 | 2024-2025 | Proclaim |
| Medtronic, INC. | $173.03 | 2023-2024 | Vanta Adaptivestim, Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $132.89 | 2023-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $116.84 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.40 | 2019-2020 | |
| Corcept Therapeutics | $84.77 | 2024 | Korlym |
| Kowa Pharmaceuticals America, INC. | $80.67 | 2025 | Zoryve |
| Astellas Pharma US INC | $71.72 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $68.84 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $55.60 | 2023 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.83 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $39.10 | 2020-2021 | |
| Bolton Medical INC | $37.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.21 | 2021 | |
| Exact Sciences Corporation | $22.94 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $22.34 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.24 | 2019 | |
| Genzyme Corporation | $16.62 | 2021 | |
| Novo Nordisk INC | $15.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.84 | 2025 | Trintellix |
| Eisai INC. | $14.55 | 2022 | |
| Dexcom, INC. | $13.62 | 2025 | Dexcom G6 Transmitter |
| Corium, LLC | $13.14 | 2025 | Azstarys |
| Orexo US, INC. | $12.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sammy Lerma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.